These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 14755929)

  • 1. [HDL-cholesterol-- active or passive participant in the pathogenesis of atherosclerosis].
    Artenie R; Ungureanu D; Artenie A; Botnariu G; Anisie E
    Rev Med Chir Soc Med Nat Iasi; 2003; 107(2):282-7. PubMed ID: 14755929
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [HDL-cholesterol--active or passive participant in the pathogenesis of atherosclerosis? (II)].
    Artenie A; Artenie R; Ungureanu D; Botnariu G; Anisies E; Ionescu SD; Cosovanu A
    Rev Med Chir Soc Med Nat Iasi; 2004; 108(3):503-8. PubMed ID: 15832963
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Increased triglycerides and/or low HDL cholesterol. A risk factor needing treatment?].
    Steinmetz A
    MMW Fortschr Med; 2002 Aug; 144(31-32):20-3. PubMed ID: 12422724
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lipoproteins and homocyst(e)ine as risk factors for atherosclerosis: assessment and treatment.
    Frohlich JJ
    Can J Cardiol; 1995 May; 11 Suppl C():18C-23C. PubMed ID: 7750044
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The benefit of fibrates in the treatment of 'bad HDL-C responders to statins'.
    Devroey D; Velkeniers B; Duquet W; Betz W
    Int J Cardiol; 2005 May; 101(2):231-5. PubMed ID: 15882669
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of lipid modification on progression of coronary calcification.
    McCullough PA
    J Am Soc Nephrol; 2005 Nov; 16 Suppl 2():S115-9. PubMed ID: 16251246
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeting residual cardiovascular risk: raising high-density lipoprotein cholesterol levels.
    Hausenloy DJ; Yellon DM
    Heart; 2008 Jun; 94(6):706-14. PubMed ID: 18480348
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Atherosclerosis: who gets it and how it gets there.
    Ducas J
    Can J Cardiol; 1993 Mar; 9(2):160-1. PubMed ID: 8490785
    [No Abstract]   [Full Text] [Related]  

  • 9. Effects of pravastatin on coronary events in 2073 patients with low levels of both low-density lipoprotein cholesterol and high-density lipoprotein cholesterol: results from the LIPID study.
    Colquhoun D; Keech A; Hunt D; Marschner I; Simes J; Glasziou P; White H; Barter P; Tonkin A;
    Eur Heart J; 2004 May; 25(9):771-7. PubMed ID: 15120888
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Risk factors for coronary artery disease in patients with elevated high-density lipoprotein cholesterol.
    DeFaria Yeh D; Freeman MW; Meigs JB; Grant RW
    Am J Cardiol; 2007 Jan; 99(1):1-4. PubMed ID: 17196452
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [HDL and CETP in atherogenesis].
    Pöss J; Böhm M; Laufs U
    Dtsch Med Wochenschr; 2010 Feb; 135(5):188-92. PubMed ID: 20082258
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Optimal cutoff value of high-density lipoprotein cholesterol for predicting coronary artery disease in Taiwanese population.
    Huang YC; Ho CC; Lin PT; Lee BJ; Lai CH; Liaw YP
    Nutr Res; 2010 Jan; 30(1):21-6. PubMed ID: 20116656
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Focus on HDL as a therapeutic target for CAD risk reduction.
    Davidson MH
    Am J Cardiol; 2009 Nov; 104(10 Suppl):1E-2E. PubMed ID: 19895937
    [No Abstract]   [Full Text] [Related]  

  • 14. [Treatment of the patient with ideal LDL cholesterol].
    Mendoza Pérez E
    Arch Cardiol Mex; 2003; 73 Suppl 1():S98-102. PubMed ID: 12966655
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Which study conclusions favor so-called primary prevention of increased cholesterol values, which speak against prevention and what therapy guidelines are reliable?].
    Steinmetz A
    Internist (Berl); 1994 Sep; 35(9):880-1. PubMed ID: 7960571
    [No Abstract]   [Full Text] [Related]  

  • 16. Prevalence of low high-density lipoprotein cholesterol in patients with documented coronary heart disease or risk equivalent and controlled low-density lipoprotein cholesterol.
    Alsheikh-Ali AA; Lin JL; Abourjaily P; Ahearn D; Kuvin JT; Karas RH
    Am J Cardiol; 2007 Nov; 100(10):1499-501. PubMed ID: 17996508
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [The link between cholesterol and coronary atherosclerosis: epidemiological evidence].
    Richard JL
    Rev Prat; 1989 Apr; 39(12):1030-9. PubMed ID: 2662361
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Serum ferritin levels and other indicators of organic iron as risk factors or markers in coronary artery disease.
    Armaganijan D; Batlouni M
    Rev Port Cardiol; 2003 Feb; 22(2):185-95; discussion 197-201. PubMed ID: 12768999
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Effect of the LDL-/HDL-cholesterol quotient on progression and regression of arteriosclerotic lesions. An analysis of controlled angiographic intervention studies].
    Gohlke H
    Wien Klin Wochenschr; 1992; 104(11):309-13. PubMed ID: 1621390
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Influence of HDL cholesterol on preclinical carotid atherosclerosis in familial hypercholesterolemia.
    Junyent M; Cofán M; Núñez I; Gilabert R; Zambón D; Ros E
    Arterioscler Thromb Vasc Biol; 2006 May; 26(5):1107-13. PubMed ID: 16556855
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.